Am J Clin Nutr 2014
L34968) was added at a ratio of 1 L for every 10 6 cells and incubated in the dark for 30 min at room temperature
Benchmarking against SUSTAIN-6 and SURPASS-CVOT In the emulation of SUSTAIN-6 comparing semaglutide to sitagliptin, a proxy for placebo, in patients at moderate and high cardiovascular risk (Table 2 and Supplementary Table 19), the hazard ratio (HR) for the primary endpoint was 0.68 (95% confidence interval (CI) 0.600.77) compared to the trial estimate of HR 0.74 (95% CI 0.58 to 0.95)
Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study
When in fact, if we looked at that, that study a little differently, hey, maybe the medication we're using isn't working [00:50:00] and that's why people aren't getting well
18 : 573578 Santarelli M, Granato A, Sbriccoli A, Gobbi G, Janiri L, Minciacchi D
